HRP20200744T1 - Organizacija ekspresijskog vektora, novi postupci generiranja proizvodnje stanica i njihova uporaba za rekombinantnu proizvodnju polipeptida - Google Patents

Organizacija ekspresijskog vektora, novi postupci generiranja proizvodnje stanica i njihova uporaba za rekombinantnu proizvodnju polipeptida Download PDF

Info

Publication number
HRP20200744T1
HRP20200744T1 HRP20200744TT HRP20200744T HRP20200744T1 HR P20200744 T1 HRP20200744 T1 HR P20200744T1 HR P20200744T T HRP20200744T T HR P20200744TT HR P20200744 T HRP20200744 T HR P20200744T HR P20200744 T1 HRP20200744 T1 HR P20200744T1
Authority
HR
Croatia
Prior art keywords
expression
cassette
antibody
light chain
heavy chain
Prior art date
Application number
HRP20200744TT
Other languages
English (en)
Inventor
Peter Michael HUELSMANN
Hendrik Knoetgen
Original Assignee
F. Hoffmann - La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann - La Roche Ag filed Critical F. Hoffmann - La Roche Ag
Publication of HRP20200744T1 publication Critical patent/HRP20200744T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/36—Vector systems having a special element relevant for transcription being a transcription termination element

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Claims (11)

1. Ekspresijski vektor, naznačen time, da sadrži: - kazetu za ekspresiju lakog lanca protutijela, - kazetu za ekspresiju teškog lanca protutijela i - kazetu za ekspresiju selekcijskog markera, pri čemu su kazete za ekspresiju raspoređene jednosmjerno, i pri čemu su kazete za ekspresiju raspoređene u 5' do 3' sekvence kazete za ekspresiju teškog lanca protutijela, kazete za ekspresiju lakog lanca protutijela i kazete za ekspresiju selekcijskog markera, pri čemu sve tri kazete za ekspresiju sadrže promotor humanog elongacijskog faktora 1 alfa identifikacijskog broja sekvence: 05, pri čemu kazeta za ekspresiju lakog lanca i kazeta za ekspresiju teškog lanca protutijela, sadrže signalnu sekvencu polyA goveđeg hormona rasta.
2. Ekspresijski vektor u skladu s patentnim zahtjevom 1, naznačen time, da kazete za ekspresiju ne sadrže terminacijsku sekvencu.
3. Ekspresijski vektor prema bilo kojem od patentnih zahtjeva 1 do 2, naznačen time, da nukleinska kiselina koja kodira laki lanac protutijela i/ili nukleinska kiselina koja kodira teški lanac protutijela, sadrži barem jedan intron.
4. Ekspresijski vektor prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da nukleinska kiselina koja kodira laki lanac protutijela i/ili nukleinska kiselina koja kodira teški lanac protutijela je cDNA.
5. Uporaba ekspresijskog vektora prema bilo kojem od patentnih zahtjeva 1 do 4, naznačena time, da je za rekombinantnu proizvodnju protutijela.
6. Uporaba ekspresijskog vektora prema bilo kojem od patentnih zahtjeva 1 do 4, naznačena time, da je za dobivanje stabilne stanične linije.
7. Uporaba ekspresijskog vektora prema bilo kojem od patentnih zahtjeva 1 do 4, naznačena time, da je za dobivanje proizvodne stanične linije.
8. Postupak za proizvodnju protutijela, naznačen time, da obuhvaća sljedeće korake: - kultiviranje eukariotske stanice koja je transficirana ekspresijskim vektorom prema bilo kojem od patentnih zahtjeva 1 do 4, i - dobivanje protutijela iz stanice ili kultivacijskog medija.
9. Ekspresijski vektor prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time, da ekspresijski vektor sadrži: - prvu kazetu za ekspresiju koja u smjeru 5' do 3' sadrži promotor, nukleinsku kiselinu koja kodira prvi laki lanac protutijela, signalnu sekvencu polyA, i opcionalno terminacijsku sekvencu, - drugu kazetu za ekspresiju koja u smjeru 5' do 3' sadrži promotor, nukleinsku kiselinu koja kodira drugi laki lanac protutijela, signalnu sekvencu polyA, i opcionalno terminacijsku sekvencu, - treću kazetu za ekspresiju koja u smjeru 5' do 3' sadrži promotor, nukleinsku kiselinu koja kodira prvi teški lanac protutijela, signalnu sekvencu polyA, i opcionalno terminacijsku sekvencu, - četvrtu kazetu za ekspresiju koja u smjeru 5' do 3' sadrži promotor, nukleinsku kiselinu koja kodira drugi teški lanac protutijela, signalnu sekvencu polyA, i opcionalno terminacijsku sekvencu, ili - prvu kazetu za ekspresiju koja u smjeru 5' do 3' sadrži promotor, nukleinsku kiselinu koja kodira laki lanac protutijela, signalnu sekvencu polyA, i opcionalno terminacijsku sekvencu, - drugu kazetu za ekspresiju koja u smjeru 5' do 3' sadrži promotor, nukleinsku kiselinu koja kodira prvi teški lanac protutijela, signalnu sekvencu polyA, i opcionalno terminacijsku sekvencu, i - treću kazetu za ekspresiju koja u smjeru 5' do 3' sadrži promotor, nukleinsku kiselinu koja kodira drugi teški lanac protutijela, signalnu sekvencu polyA, i opcionalno terminacijsku sekvencu, pri čemu laki lanac protutijela je zajednički laki lanac za oba teška lanca protutijela.
10. Ekspresijski vektor prema bilo kojem od patentnih zahtjeva 1 do 4 i 9, naznačen time, da ekspresijski vektor sadrži: - kazetu za ekspresiju lakog lanca protutijela, - prvu kazetu za ekspresiju teškog lanca protutijela, - drugu kazetu za ekspresiju teškog lanca protutijela i - kazetu za ekspresiju selekcijskog markera, pri čemu je barem jedna od kazete za ekspresiju teškog lanca protutijela i kazete za ekspresiju lakog lanca protutijela i kazete za ekspresiju selekcijskog markera, raspoređena jednosmjerno, i pri čemu su jednosmjerne kazete za ekspresiju raspoređene u 5' do 3' sekvenci kazete za ekspresiju teškog lanca protutijela, kazete za ekspresiju lakog lanca protutijela i kazete za ekspresiju selekcijskog markera.
11. Ekspresijski vektor prema bilo kojem od patentnih zahtjeva 1 do 4 i 9 do 10, naznačen time, da ekspresijski vektor sadrži: - prvu kazetu za ekspresiju lakog lanca protutijela, - drugu kazetu za ekspresiju lakog lanca protutijela, - prvu kazetu za ekspresiju teškog lanca protutijela, - drugu kazetu za ekspresiju teškog lanca protutijela, i - kazetu za ekspresiju selekcijskog markera, pri čemu su jedna od kazeta za ekspresiju teškog lanca protutijela i jedna od kazete za ekspresiju lakog lanca protutijela i kazete za ekspresiju selekcijskog markera, raspoređene jednosmjerno, i pri čemu su jednosmjerne kazete za ekspresiju raspoređene u 5' do 3' sekvenci kazete za ekspresiju teškog lanca protutijela, kazete za ekspresiju lakog lanca protutijela i kazete za ekspresiju selekcijskog markera.
HRP20200744TT 2011-12-22 2020-05-08 Organizacija ekspresijskog vektora, novi postupci generiranja proizvodnje stanica i njihova uporaba za rekombinantnu proizvodnju polipeptida HRP20200744T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11195363 2011-12-22
EP12813822.9A EP2794878B1 (en) 2011-12-22 2012-12-19 Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
PCT/EP2012/076167 WO2013092723A1 (en) 2011-12-22 2012-12-19 Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides

Publications (1)

Publication Number Publication Date
HRP20200744T1 true HRP20200744T1 (hr) 2020-07-24

Family

ID=47557065

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20200744TT HRP20200744T1 (hr) 2011-12-22 2020-05-08 Organizacija ekspresijskog vektora, novi postupci generiranja proizvodnje stanica i njihova uporaba za rekombinantnu proizvodnju polipeptida

Country Status (16)

Country Link
US (3) US9963511B2 (hr)
EP (2) EP3816284A1 (hr)
JP (4) JP2015502165A (hr)
KR (3) KR102080356B1 (hr)
CN (2) CN104114701A (hr)
BR (1) BR112014012667A2 (hr)
CA (2) CA2853955C (hr)
ES (1) ES2791758T3 (hr)
HK (2) HK1203546A1 (hr)
HR (1) HRP20200744T1 (hr)
MX (1) MX355625B (hr)
PL (1) PL2794878T3 (hr)
RU (2) RU2628703C2 (hr)
SG (3) SG11201403223PA (hr)
SI (1) SI2794878T1 (hr)
WO (1) WO2013092723A1 (hr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3816284A1 (en) 2011-12-22 2021-05-05 F. Hoffmann-La Roche AG Expression vector for antibody production in eukaryotic cells
WO2016011448A2 (en) * 2014-07-18 2016-01-21 Celltheon Corporation Methods and compositions for expression of polypeptides in a cell
SG11202103334YA (en) * 2018-10-26 2021-05-28 Hoffmann La Roche Multispecific antibody screening method using recombinase mediated cassette exchange
MX2021015193A (es) * 2019-06-28 2022-01-18 Hoffmann La Roche Metodo para la produccion de un anticuerpo.
US12116578B2 (en) 2019-08-07 2024-10-15 APDN (B.V.1.) 1nc. Methods and systems of PCR-based recombinant adeno-associated virus manufacture
CN112626121B (zh) * 2020-12-29 2024-04-09 苏州博腾生物制药有限公司 三筛选标记的抗体表达载体以及应用
CN113512537A (zh) * 2021-08-19 2021-10-19 长春生物制品研究所有限责任公司 高表达人促卵泡激素的重组cho细胞株及其构建方法

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
JP3051411B2 (ja) 1989-03-14 2000-06-12 持田製薬株式会社 新規ｄｎａならびにそれを含有する発現プラスミド
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5574205A (en) 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6440418B1 (en) * 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6207455B1 (en) * 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
AU757627B2 (en) 1997-06-24 2003-02-27 Genentech Inc. Methods and compositions for galactosylated glycoproteins
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
ATE419009T1 (de) 1997-10-31 2009-01-15 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
AU5755399A (en) * 1998-09-16 2000-04-03 Nexia Biotechnologies, Inc. Recombinant protein production in urine
KR20000046969A (ko) 1998-12-31 2000-07-25 이선경 이종 유전자 유래의 유전자 발현 조절요소를 포함하는 강력한전사 활성을 가진 진핵세포 발현벡더
EP2275541B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
PT1222292E (pt) 1999-10-04 2005-11-30 Medicago Inc Metodo para regulacao da transcricao de genes exogenos na presenca de azoto
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US7504256B1 (en) 1999-10-19 2009-03-17 Kyowa Hakko Kogyo Co., Ltd. Process for producing polypeptide
JP2003516755A (ja) 1999-12-15 2003-05-20 ジェネンテック・インコーポレーテッド ショットガン走査、すなわち機能性タンパク質エピトープをマッピングするための組み合わせ方法
SK288711B6 (sk) 2000-02-24 2019-11-05 Univ Washington Humanizovaná protilátka, jej fragment a ich použitie, polynukleová kyselina, expresný vektor, bunka a farmaceutický prostriedok
EP1272647B1 (en) 2000-04-11 2014-11-12 Genentech, Inc. Multivalent antibodies and uses therefor
AU2001261628A1 (en) * 2000-05-16 2001-11-26 Euroceltique S.A. Cd28 synthebody for the modulation of immune responses
KR100408844B1 (ko) 2000-07-29 2003-12-06 한국산업기술평가원 동물세포 발현벡터
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
EA013224B1 (ru) 2000-10-06 2010-04-30 Киова Хакко Кирин Ко., Лтд. Клетки, продуцирующие композиции антител
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ATE503012T1 (de) * 2000-11-17 2011-04-15 Kyowa Hakko Kirin Co Ltd Expression von xenogenen (humanen) immunglobulinen in klonierten, transgenen huftieren
PT1354034E (pt) 2000-11-30 2008-02-28 Medarex Inc Roedores transgénicos transcromossómicos para produção de anticorpos humanos
NZ545176A (en) 2001-01-29 2008-05-30 Biogen Idec Inc Modified antibodies reactive with CD20 and methods of use
WO2002101006A2 (en) 2001-06-08 2002-12-19 Icon Genetics, Inc. Production of proteins in plants
NZ592087A (en) 2001-08-03 2012-11-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
EP1438075A4 (en) * 2001-10-02 2006-04-19 Inst Clayton De La Rech METHOD AND COMPOSITIONS ASSOCIATED WITH LENTIVIRAL VECTORS WITH LIMITED EXPRESSION AND ITS APPLICATIONS
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
AU2002337935B2 (en) 2001-10-25 2008-05-01 Genentech, Inc. Glycoprotein compositions
CA2467363A1 (en) 2001-11-16 2003-06-12 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20030215858A1 (en) 2002-04-08 2003-11-20 Baylor College Of Medicine Enhanced gene expression system
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
ES2362419T3 (es) 2002-04-09 2011-07-05 Kyowa Hakko Kirin Co., Ltd. Células con depresión o deleción de la actividad de la proteína que participa en el transporte de gdp-fucosa.
WO2003085107A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cellules à génome modifié
JP4832719B2 (ja) 2002-04-09 2011-12-07 協和発酵キリン株式会社 ＦｃγＲＩＩＩａ多型患者に適応する抗体組成物含有医薬
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
AU2003236017B2 (en) 2002-04-09 2009-03-26 Kyowa Kirin Co., Ltd. Drug containing antibody composition
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
PT1572744E (pt) 2002-12-16 2010-09-07 Genentech Inc Variantes de imunoglobulina e utilizações destas
MXPA05006724A (es) 2003-01-07 2005-09-08 Symphogen As Metodo para producir proteinas policlonales recombinantes.
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
CN1798767B (zh) * 2003-04-10 2011-02-16 晶面生物技术公司 通过诱变来改变抗体对FcRn的结合亲和力或血清半衰期
US7902338B2 (en) * 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP1688439A4 (en) 2003-10-08 2007-12-19 Kyowa Hakko Kogyo Kk HYBRID PROTEIN COMPOSITION
EP1705251A4 (en) 2003-10-09 2009-10-28 Kyowa Hakko Kirin Co Ltd PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY RNA INHIBITION OF FUNCTION OF $ G (A) 1,6-FUCOSYLTRANSFERASE
SG10202008722QA (en) 2003-11-05 2020-10-29 Roche Glycart Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
EP1733034A4 (en) 2004-03-15 2010-01-20 Biogen Idec Inc METHOD AND CONSTRUCTS FOR THE EXPRESSION OF POLYPEPTIDE MULTIMERS IN EUKARYONTIC CELLS USING ALTERNATIVE SPLEISSEN
JP5128935B2 (ja) 2004-03-31 2013-01-23 ジェネンテック， インコーポレイテッド ヒト化抗ＴＧＦ−β抗体
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
EP2360186B1 (en) 2004-04-13 2017-08-30 F. Hoffmann-La Roche AG Anti-P-selectin antibodies
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
EP1910421B1 (en) 2005-05-18 2019-03-13 Biofactura, Inc Compositions and methods for metabolic selection of transfected cells
WO2007045465A1 (en) 2005-10-21 2007-04-26 F. Hoffmann-La Roche Ag Method for the recombinant expression of a polypeptide
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
JP2009536527A (ja) 2006-05-09 2009-10-15 ジェネンテック・インコーポレーテッド 最適化されたスキャフォールドを備えた結合ポリペプチド
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
WO2008077545A1 (en) 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Selection method
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN100999732A (zh) * 2006-12-30 2007-07-18 北京济普霖生物技术有限公司 一种利用动物乳腺生产抗人cd20单克隆抗体的方法
JP5432117B2 (ja) 2007-03-30 2014-03-05 アッヴィ・インコーポレイテッド 宿主細胞中の組換えタンパク質の発現を増進するための組換え発現ベクター要素（ｒＥＶＥ）
EP1995309A1 (en) * 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
US9080183B2 (en) 2007-06-29 2015-07-14 Hoffmann-La Roche Inc. Promoter
EP2207881A1 (en) 2007-10-12 2010-07-21 F. Hoffmann-Roche AG Protein expression from multiple nucleic acids
PT2227546T (pt) 2007-12-21 2016-08-12 Novartis Ag Vector de expressão em mamíferos
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
HUE028536T2 (en) 2008-01-07 2016-12-28 Amgen Inc Method for producing antibody to FC heterodimer molecules using electrostatic control effects
CN101550425B (zh) * 2008-03-31 2011-03-30 北京大学 一种可调控的肝损伤动物模型的制作方法及其专用载体
ES2906344T3 (es) 2008-06-27 2022-04-18 Merus Nv Animal murino transgénico productor de anticuerpos
JP5788796B2 (ja) 2008-08-28 2015-10-07 ノバルティス アーゲー 終止コドンのリードスルーによるポリペプチドアイソフォームの細胞表面提示
GB0903207D0 (en) 2009-02-25 2009-04-08 Ucb Pharma Sa Method for expressing multimeric proteins
RU2598248C2 (ru) 2009-04-02 2016-09-20 Роше Гликарт Аг Полиспецифичные антитела, включающие антитела полной длины и одноцепочечные фрагменты fab
PL2417156T3 (pl) 2009-04-07 2015-07-31 Roche Glycart Ag Trójwartościowe, bispecyficzne przeciwciała
CA2761233A1 (en) 2009-05-27 2010-12-02 F. Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
JP4525863B1 (ja) 2009-06-05 2010-08-18 東洋紡績株式会社 高生産性細胞の樹立のための発現ベクター及び高生産性細胞
JP4547643B1 (ja) * 2009-06-05 2010-09-22 東洋紡績株式会社 クローニングに最適化された発現ベクター
CN101596316A (zh) * 2009-06-12 2009-12-09 长沙新生康源生物医药有限公司 表达FoxMlsiRNA的重组腺病毒及其在肿瘤治疗和预防中的应用
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
KR20120099376A (ko) * 2009-09-18 2012-09-10 셀렉시스 에스. 에이. 강화된 전이 유전자 발현과 공정 방법 및 그 산물
JP5506339B2 (ja) 2009-11-19 2014-05-28 三菱重工業株式会社 方向制御装置および方向制御方法
WO2012017003A1 (en) 2010-08-05 2012-02-09 F. Hoffmann-La Roche Ag Anti-mhc antibody anti-viral cytokine fusion protein
CN107312796A (zh) 2010-12-15 2017-11-03 大学共同利用机关法人情报·系统研究机构 蛋白质的生产方法
EP3816284A1 (en) * 2011-12-22 2021-05-05 F. Hoffmann-La Roche AG Expression vector for antibody production in eukaryotic cells
KR102288857B1 (ko) 2013-12-20 2021-08-11 노파르티스 아게 신규한 진핵 세포 및 관심 생성물의 재조합 발현 방법

Also Published As

Publication number Publication date
SG10201805622QA (en) 2018-08-30
JP2017060519A (ja) 2017-03-30
RU2014129729A (ru) 2016-02-20
EP3816284A1 (en) 2021-05-05
BR112014012667A8 (pt) 2017-06-20
CN104114701A (zh) 2014-10-22
US20210054083A1 (en) 2021-02-25
KR102184059B1 (ko) 2020-11-30
RU2017127208A (ru) 2019-02-14
KR20200133827A (ko) 2020-11-30
SG11201403223PA (en) 2014-07-30
KR102080356B1 (ko) 2020-02-24
JP2021072867A (ja) 2021-05-13
SG10201601882PA (en) 2016-04-28
KR102280111B1 (ko) 2021-07-21
JP2019071903A (ja) 2019-05-16
ES2791758T3 (es) 2020-11-05
CN107881196A (zh) 2018-04-06
EP2794878B1 (en) 2020-03-18
CA2853955A1 (en) 2013-06-27
CA3125875A1 (en) 2013-06-27
US10882910B2 (en) 2021-01-05
HK1203546A1 (en) 2015-10-30
US9963511B2 (en) 2018-05-08
SI2794878T1 (sl) 2020-07-31
KR20140113915A (ko) 2014-09-25
MX2014007360A (es) 2014-08-01
WO2013092723A1 (en) 2013-06-27
HK1250743A1 (zh) 2019-01-11
RU2756106C2 (ru) 2021-09-28
US20140370547A1 (en) 2014-12-18
MX355625B (es) 2018-04-25
PL2794878T3 (pl) 2020-07-27
EP2794878A1 (en) 2014-10-29
JP7057456B2 (ja) 2022-04-19
CA2853955C (en) 2021-09-28
US20180334505A1 (en) 2018-11-22
BR112014012667A2 (pt) 2018-10-09
JP2015502165A (ja) 2015-01-22
RU2017127208A3 (hr) 2021-04-02
KR20200008017A (ko) 2020-01-22
RU2628703C2 (ru) 2017-08-21

Similar Documents

Publication Publication Date Title
HRP20200744T1 (hr) Organizacija ekspresijskog vektora, novi postupci generiranja proizvodnje stanica i njihova uporaba za rekombinantnu proizvodnju polipeptida
HRP20221383T1 (hr) Kombinacije elemenata ekspresijskog vektora, novi proizvodni postupci dobivanja stanica i njihova uporaba za rekombinantnu proizvodnju polipeptida
JP2010519251A5 (hr)
FI3536797T3 (fi) Siirtogeenin tehostettu ilmentäminen ja prosessointi
MX338036B (es) Expresion proteinica a partir de acidos nucleicos multiples.
JP2017501712A (ja) 単鎖ｉｌ−１２核酸、ポリペプチド、およびそれらの使用
CL2012001258A1 (es) Un polipeptido de factor de von willebrand (fvw) aislado que comprende un dominio de union a factor viii (fviii), donde dicho polipeptido carece de algunos dominios del fvw, comprende una secuencia de aminoacidos de fc de inmunoglobulina; composicion y complejo proteico que lo comprende; celula que expresa dicho polipeptido; celula que expresa dicho complejo proteico; composición que comprende el complejo proteico.
HRP20240855T1 (hr) Neljudske životinje koje imaju humanizirani gen cd274 iz diferencijacijske skupine
IL275497B (en) Serum proteins with type iii fibronectin binding domains
ES2780692T3 (es) Constructo y secuencia para la expresión genética mejorada
MX2015012361A (es) Metodos de fabricacion para controlar el contenido de lisina c-terminal, galactosa y acido sialico en proteinas recombinantes.
MX2020008470A (es) Vectores de adn no virales y usos de estos para la produccion de anticuerpos y proteinas de fusion.
JP2016517691A5 (hr)
JP2019514417A5 (hr)
RU2020110331A (ru) Модификация т-клеток
TR201816314T4 (tr) Kimerik sitomegalovirüs promotörü ve güçlendirici dizileri içeren ekspresyon vektörleri.
HRP20210301T1 (hr) Djelotvorna selektivnost rekombinantnih proteina
Al-Rubeai Antibody expression and production
ES2564227T3 (es) Elemento de ADN que tiene actividad de aumento de expresión de un gen exógeno
JP2014527801A5 (hr)
CN102659928A (zh) 一种人工合成的信号肽及其应用
JP2016506239A5 (hr)
JP2014518611A5 (hr)
CN106478773A (zh) 一种人工合成的新型信号肽
JP2008543283A (ja) インスレーターエレメントを含むベクターを使用する抗体発現の改良